Ptc Therapeutics (PTCT) Short term Debt (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Short term Debt of $314.2 million for Q2 2026, up 19.92% year-over-year from $262.0 million in Q2 2025, and up 3.01% quarter-over-quarter from $305.0 million in Q1 2026.
Ptc Therapeutics (PTCT) Short term Debt (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Short term Debt history runs 12 years deep, the most recent figure standing at $314.2 million for Q2 2026.
- In Q2 2026, Short term Debt rose 19.92% year-over-year to $314.2 million; the TTM figure through Jun 2026 stood at $314.2 million (up 19.92% YoY), while the FY2025 annual figure was $286.6 million, up 11.17% from the prior year.
- Short term Debt for Q2 2026 stood at $314.2 million, up from $305.0 million in the prior quarter.
- The five-year high for Short term Debt was $314.2 million in Q2 2026, with the low at $72.1 million in Q4 2022.
- The 5-year median for Short term Debt is $237.7 million (2024), against an average of $203.0 million.
- Peak annual rise in Short term Debt reached 351.66% in 2022, while the deepest fall reached 51.75% in 2022.
- Ptc Therapeutics' Short term Debt stood at $72.1 million in 2022, then jumped by 169.32% to $194.3 million in 2023, then soared by 32.68% to $257.8 million in 2024, then advanced by 11.17% to $286.6 million in 2025, then advanced by 9.62% to $314.2 million in 2026.
- Business Quant data shows PTCT's Short term Debt at $314.2 million in Q2 2026, $305.0 million in Q1 2026, and $286.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 314.22 Mn |
| Mar 31, 2026 | 305.04 Mn |
| Dec 31, 2025 | 283.00 Mn |
| Sep 30, 2025 | 286.32 Mn |
| Jun 30, 2025 | 262.02 Mn |
| Mar 31, 2025 | 248.24 Mn |
| Dec 31, 2024 | 257.82 Mn |
| Sep 30, 2024 | 257.61 Mn |
| Jun 30, 2024 | 255.00 Mn |
| Mar 31, 2024 | 227.10 Mn |
| Dec 31, 2023 | 194.31 Mn |
| Sep 30, 2023 | 105.85 Mn |
| Jun 30, 2023 | 105.35 Mn |
| Mar 31, 2023 | 97.87 Mn |
| Dec 31, 2022 | 72.15 Mn |
| Sep 30, 2022 | 77.96 Mn |
| Jun 30, 2022 | 149.91 Mn |
| Mar 31, 2022 | 69.94 Mn |
| Dec 31, 2021 | 149.54 Mn |
| Sep 30, 2021 | 52.65 Mn |